PTD-DBM vs SYN-AKE
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CXXC5-Dishevelled disrupting peptide, Protein Transduction Domain-Dishevelled Binding Motif
PTD-DBM is a synthetic peptide studied for hair regrowth. It pairs a cell-penetrating protein transduction domain with a Dishevelled-binding motif, letting it slip into cells and block CXXC5, a natural brake on the Wnt/beta-catenin pathway that hair follicles use to enter their growth phase. In mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. The honest catch: the entire efficacy record is preclinical and comes mostly from one lab. There are no completed human trials, no regulatory approval, and no proof it works on people. For research use only.
Also: Dipeptide diaminobutyroyl benzylamide diacetate, SYN-AKE
SYN-AKE is DSM's trade name for dipeptide diaminobutyroyl benzylamide diacetate, the 'snake venom' peptide in a lot of anti-wrinkle creams. The marketing says it mimics Waglerin-1, a toxin from the temple viper. To be clear: there is no venom in it. It is a tiny synthetic molecule, and the evidence that it relaxes wrinkles comes almost entirely from the manufacturer.
Key Comparison Insights
- Both peptides belong to the Skin & Hair category, suggesting similar primary applications.
- PTD-DBM has stronger research evidence (Animal Studies) compared to SYN-AKE (Limited Research).
Detailed Comparison
| Attribute | PTD-DBM | SYN-AKE |
|---|---|---|
| Category | Skin & Hair | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Hair follicles cycle into their growth (anagen) phase when Wnt/beta-catenin signaling switches on. CXXC5 is a negative feedback regulator of that pathway: it binds the intracellular protein Dishevelled (Dvl) and holds Wnt signaling down. PTD-DBM is a short Dvl-binding motif fused to a protein transduction domain (for cell entry) that competitively disrupts the CXXC5-Dvl interaction. With CXXC5 displaced, Dvl is free to activate Wnt/beta-catenin, which drives follicle stem-cell activation, anagen entry, and wound-induced hair neogenesis (new follicle formation in healing skin). It is typically studied together with valproic acid, a GSK-3beta inhibitor that pushes the same pathway from a different angle, so the two produce a synergistic effect greater than either alone. Be blunt: this mechanism is worked out in mice and cell models. The pathway is well characterized, but none of it has been validated in humans. | DSM describes SYN-AKE as a reversible blocker of the muscle-type nicotinic acetylcholine receptor, the receptor on muscle that acetylcholine opens to make it contract. Block it, the theory goes, and facial muscles relax a little. That is the real mechanism of Waglerin-1, a 22-amino-acid viper toxin that independent research shows selectively blocks the adult form of this receptor. SYN-AKE itself is a much smaller molecule (beta-alanine, proline and diaminobutyric acid with a benzylamide end, under 500 daltons), and the claim that it does the same thing comes from the manufacturer's own cell test, where innervated muscle cells contracted less. Even DSM's older material calls the binding 'probable'. As with Argireline, there is no independent proof that a cream gets enough of it to facial muscle to matter. |
| Common Dosing | Supplied as 1 mg or 5 mg vials. A 5 mg vial in about 1 mL of water approximates the ~6 mg/mL used in the mouse study Once daily to the scalp in most community-reported routines | 1-4% of the SYN-AKE solution in a finished product Once or twice daily |
| Administration | Topical (applied to skin) in published research; usually co-applied with valproic acid | Topical (serums, creams) |
| Typical Duration | Applied over several weeks in animal studies | 28 days in the manufacturer study; ongoing use to maintain any effect |
| Best Time to Take | Not established (topical in animal studies) | Morning and/or evening, on clean skin |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core evidence comes from Lee SH and colleagues in the Choi laboratory at Yonsei University (South Korea), published in the Journal of Investigative Dermatology in 2017. In mice, topical PTD-DBM sped up the onset of anagen after shaving and promoted wound-induced hair neogenesis; a topical liquid of about 6 mg/mL PTD-DBM plus about 72 mg/mL valproic acid outperformed roughly 2% minoxidil in that model (the study reported these as solution concentrations: 2 mM, 500 mM, and 100 mM). The compound and its CXXC5-targeting mechanism are cited in more recent review articles on Wnt/beta-catenin hair therapies and short peptides for hair loss (2024-2025). What does not exist, as of 2026, is a single completed, peer-reviewed human efficacy trial. There is no FDA approval and no IND on record. Human dosing, safety, pharmacokinetics, and real-world efficacy are all unknown. The preclinical signal is genuinely interesting, but it is a long way from a proven treatment. | DSM's brochure reports two pieces of data. In vitro, 0.5 mM of the peptide cut the contraction frequency of innervated muscle cells. In vivo, a 4% SYN-AKE cream was compared with placebo in 15 volunteers per group (aged 40-60), applied twice daily for 28 days, with reductions of roughly 15-21% in skin roughness and wrinkle measures and a headline of 'up to 52%' wrinkle reduction in the best responders. A US patent also describes a double-blind study in 59 women aged 40-55 reporting smaller pores and less shine after 28 days, but that is a patent filing, not a peer-reviewed paper. A 2020 review of cosmetic peptides states plainly that there are no scientific papers describing clinical studies of this peptide, so the efficacy story rests on company data. Bottom line: a well-tolerated cosmetic ingredient with a catchy story. The venom angle is marketing, and the 'up to 52%' number is a best case from a 15-person company study, not a typical result. |
Frequently Asked Questions: PTD-DBM vs SYN-AKE
What is the difference between PTD-DBM and SYN-AKE?
PTD-DBM is a skin & hair peptide that ptd-dbm is a synthetic peptide studied for hair regrowth. it pairs a cell-penetrating protein transduction domain with a dishevelled-binding motif, letting it slip into cells and block cxxc5, a natural brake on the wnt/beta-catenin pathway that hair follicles use to enter their growth phase. in mouse studies, releasing that brake (usually alongside topical valproic acid) restarted hair growth and even formed new follicles in wounded skin. the honest catch: the entire efficacy record is preclinical and comes mostly from one lab. there are no completed human trials, no regulatory approval, and no proof it works on people. for research use only. SYN-AKE is a skin & hair peptide that syn-ake is dsm's trade name for dipeptide diaminobutyroyl benzylamide diacetate, the 'snake venom' peptide in a lot of anti-wrinkle creams. the marketing says it mimics waglerin-1, a toxin from the temple viper. to be clear: there is no venom in it. it is a tiny synthetic molecule, and the evidence that it relaxes wrinkles comes almost entirely from the manufacturer. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PTD-DBM or SYN-AKE?
Neither is universally "better" - the choice depends on your specific goals. PTD-DBM is typically used for skin & hair purposes, while SYN-AKE is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PTD-DBM and SYN-AKE be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PTD-DBM and SYN-AKE together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.